This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Accretive transaction accelerates Endo's transformation into a leading specialty healthcare company
Creates a compelling financial and operational platform for future growth
Establishes Endo's global pharmaceuticals footprint
Endo Health Solutions Inc. becomes Endo International plc
Endo International plc (Nasdaq: ENDP; TSX: ENL), formerly Endo Health Solutions Inc., announced today that it has completed the acquisition of Paladin Labs Inc. in a stock and cash transaction currently valued at approximately
$2.7 billion. The acquisition accelerates Endo's strategic transformation into a leading global specialty healthcare company and creates a platform for future growth in
North America and around the globe.
In connection with the acquisition, Endo and Paladin Labs have been combined under a new company incorporated in
Ireland named Endo International plc. Shares of Endo International plc will trade on NASDAQ under the ticker symbol ENDP and the Toronto Stock Exchange under the ticker symbol ENL.
Under the terms of the transaction, Paladin Labs shareholders received 1.6331 shares of Endo International plc stock and
$1.16 (CAD) in cash for each Paladin Labs share they owned upon closing. In addition, for each Paladin Labs share owned at closing, shareholders of Paladin Labs received one share of Knight Therapeutics Inc., ("Knight Therapeutics") a newly formed Canadian company that has been separated as part of the transaction. Shareholders of Endo Health Solutions received one share of Endo International plc for each share of Endo Health Solutions Inc. they owned upon closing.
"The combination of Endo and Paladin Labs accelerates Endo's transformation into a leading global specialty healthcare company and establishes a platform for additional strategic acquisitions," said
Rajiv De Silva, president and chief executive officer of Endo. "Endo will continue with a sharp strategic focus, lean operating model and improved execution of core businesses. Strategic acquisitions will also continue to play a key role in maximizing our growth potential and creating value for Endo International shareholders."